Coronavirus (COVID-19) vaccination rates among adults who live in England, including estimates by socio-demographic characteristic and Standard Occupational Classification (SOC) 2020

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

Includes: Patient demographics, Source Organisation, vaccination details and vaccine batch events. Its scope covers: Anyone vaccinated within England Anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include: hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

Vaccination rates and odds ratios by socio-demographic group among people living in England.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

https://www.gov.uk/vaccine-damage-payment/if-you-disagree-with-a-decision

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.This dataset has been updated to reflect new age bandings and population figures provided in July 2022.This dataset now includes details of the Autumn Booster programme.Note on analysis:This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:- Aged 5 - 15 - Dose 1- Aged 16 - 24 - Dose 1 & Dose 2- Aged 35 - 50 - Dose 1, Dose 2 & Booster- Aged 50+ - Dose1, Dose2, Booster & Autumn BoosterData is updated weekly.

Antibody data, by UK country and age, from the Coronavirus (COVID-19) Infection Survey.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Flu vaccine uptake (%) in school aged children from Reception to Year 6 (age 4 to 11 year olds) between 1st September to the end of January.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in school aged children in Reception to Year 6 (age 4 to 11 years old).Definition of numeratorThe total number of children in the respective eligible age cohort that have received at least one dose of influenza vaccine from 1 September in school, pharmacy, and general practice.Definition of denominatorThe total number of children eligible for influenza vaccination in the LA geography and children educated out of school in the LA geography, defined by child age on 31 AugustCaveatsData for ICBs are estimated from local authority data. In most cases, ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on the population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and WiltshireBedfordshire, Luton and Milton KeynesBuckinghamshire, Oxfordshire and Berkshire WestCambridgeshire and PeterboroughFrimleyHampshire and Isle of WightHertfordshire and West EssexHumber and North YorkshireLancashire and South CumbriaNorfolk and WaveneyNorth East and North CumbriaSuffolk and North East EssexSurrey HeartlandsSussexWest YorkshireRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus may fall outside the listed read codes. Therefore, it is important to note that for the reasons mentioned, this data should not be used for GP payment purposes.This collection is regularly submitted for approval from the Data Coordination Board (DCB).

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. Question 1 How many claims have been made to the VDPS due to an adverse reaction to a covid vaccine to date? 16,824 claims have been received by the Vaccine Damage Payment Scheme (VDPS). Question 2– How many claimants have been notified of an outcome? 8,806 claimants have been notified of an outcome. Question 3 – Please provide a breakdown of the vaccines involved in the claims that have received an outcome? Of the 8,806 claims which have received an outcome, 4,107 relate to AstraZeneca, 3,034 relate to Pfizer, 445 relate to Moderna and 1,220 relate to other vaccines, or more than one COVID-19 vaccine and therefore we are unable to categorise them. For example, where a claim relates to an initial vaccine from one manufacturer and a booster from another. Question 4 – How many claims have been successful? Please provide a breakdown of which vaccine were used in the claims awarded. Since disclosure of FOI-02252 whereby 188 claimants were notified they were entitled to a Vaccine Damage Payment, this number has increased by fewer than 5. Of the total number of successful claimants, fewer than five were Pfizer and Moderna and the remaining claims were AstraZeneca. Therefore, as detailed above in accordance with section 40 (2) and section 41 of FOIA, we are unable to provide an updated breakdown by manufacturer. Question 5– How many claims have been rejected / unsuccessful? Please be advised since the disclosure of FOI-02252 where we disclosed 7,748 claims have been rejected, and a further 716 did not meet the criteria for medical assessment, these figures have increased by fewer than five. We have therefore decided not to disclose this exact figure under section 40 (2) and section 41 of the FOIA because the small changes in numbers when compared to figures provided previously could result in claimants being identified. Details of these exemptions are outlined above. Question 6a – What are the reasons for claims being rejected (causation, not meeting 60% threshold, ineligible to claim.) Please provide numbers? Please provide a breakdown of which vaccine was used in the claims when causation was accepted.

Does the performance of the EU compared to neighbouring countries affect popular support for the EU? Following the benchmarking approach, we argue that people compare the performance of their country inside the EU with that of a country outside the EU and, as a result of this comparison, form their attitudes towards the EU. The COVID-19 vaccine rollout in 2020 represents an ideal scenario to test this benchmarking expectation. While the pandemic challenged countries across the globe simultaneously, the speed at which governments launched their vaccination programs differed. The UK rolled out its vaccines weeks before EU countries, and we study whether this affected popular support for the EU. We conduct an Unexpected Event during Surveys Design (UESD) based on a Eurobarometer survey in the field when the first vaccine was administered in the UK. Our results show that the start of the COVID-19 vaccination in the UK led to a significant decrease in specific policy support for the EU, while there is no consistent evidence of change in diffuse support for the EU. Our article has important implications for understanding attitudes toward European integration and performance evaluations.

Includes: Patient demographics, Source Organisation, Adverse reaction details. Its scope covers: Anyone vaccinated within England and anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

Request ‘Question 1: How much money has so far been allocated to those affected by a Covid vaccination via the Vaccine Damages Payment Scheme? Question 2: How many individuals have made an application to the Vaccine Damages Payment Scheme having been affected by Guillain-Barre syndrome following a coronavirus vaccination? Question 3: How many applications to the Vaccine Damage Payment Scheme following a coronavirus vaccination have successfully resulted in a pay-out in total? Question 4: How many applicants who applied to the Vaccine Damages Payment Scheme on the basis of a Guillain-Barre syndrome diagnosis following a coronavirus vaccination have been successful in their applications and received a payment? (Please also include the number of such applications which remain outstanding and the number of applications which have been rejected) Question 5: How many applicants to the Vaccine Damage Payment Scheme who applied on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination were declined on the basis of not meeting the 60% 'severe disability' threshold? Question 6: How many applicants to the Vaccine Damage Payment Scheme who applied on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination were declined on the basis that a full or partial recovery was considered to be likely? Question 7: How many individuals made applications to the Vaccine Damage Payment Scheme in Angus, Scotland and how many of these applications were successful, are still outstanding or were unsuccessful? Question 8: How many applications in Angus Scotland to the Vaccine Damage Payment Scheme were made on the basis of a diagnosis of Guillain-Barre syndrome following a coronavirus vaccination? (Please also include how many of these applications were successful, unsuccessful and remain outstanding)’ [On 15 March 2024 you clarified your request as follows] ‘With regard to question 1 I can confirm that my query relates to the total value of Vaccine Damage Payments awarded to COVID-19 claimants rather than the total costs associated with administering the VDPS scheme.’ [On 9 April 2024 your clarified your request as follows] ‘I can confirm that question 7 relates to the claims to the Vaccine Damage Payment which relate to a COVID-19 vaccination. I can confirm that in question 7 & 8 by 'Angus' I intended to refer to the UK Parliamentary constituency of Angus if this information is available. If this information is not available in relation to the Angus UK Parliamentary Constituency, then it would be greatly appreciated if the Angus Council local authority area could be considered for these responses instead.’ Response All data as of 15 March 2024. All data relates to claims received by the NHS Business Services Authority (NHSBSA) and those transferred from the Department for Work and Pensions (DWP) on 1 November 2021. All figures provided relate to COVID-19 vaccines. Fewer than five Please be aware that I have decided not to release the full details where the total number of individuals falls below five. This is because the individuals could be identified, when combined with other information that may be in the public domain or reasonably available. This information falls under the exemption in section 40 subsections 2 and 3 (a) of the Freedom of Information Act (FOIA). This is because it would breach the first data protection principle as: a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Patient confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. https://www.legislation.gov.uk/ukpga/2000/36/section/41 Question 1 The Vaccine Damage Payment Scheme (VDPS) is not a compensation scheme. It provides a one-off tax-free payment, currently £120,000, to successful applicants where, on very rare occasions, a vaccine has caused severe disablement. The total amount of money awarded to claimants is £20,040,000.00. Question 2 The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. 183 Guillain-Barre syndrome (GBS) claims have been received by the VDPS. Question 3 167 claimants have been notified they are entitled to a Vaccine Damage Payment. Question 4 The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. Therefore, the total number of GBS claims awaiting independent medical assessment is unknown. 51 GBS claims have been awarded a Vaccine Damage Payment. 132 GBS claims have been rejected. Question 5 64 GBS claims were unsuccessful because, although the claims met the criteria for causation, the independent medical assessor recommended that the vaccine has not caused severe disablement. Under the VDPS, severe disablement means at least 60% disabled, based on Schedule 2 of The Social Security (General Benefit) Regulations 1982. Question 6 In order to determine if this information is held, we would need to manually review the independent medical assessments for all 64 GBS claims. Using a conservative estimate of 20 minutes per claim we estimate that to review all 64 claims, it would take approx. 19.2 hours to determine if we hold the information and to then provide a figure. Therefore, I estimate that the cost of complying with your request would exceed the non-central Government limit of £450. The limit has been specified in The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 and represents the estimated cost of one person spending 18 hours in determining whether the NHSBSA holds the information, and locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act, the NHSBSA is not obliged to comply with your request, and I will not be processing your request further as it currently stands. Question 7 10 individuals within the Parliamentary Constituency of Angus made an application for a Vaccine Damage Payment. We have decided not to disclose the number of claims within each status. This is because disclosure of the figures within this response, may lead to the re-identification of individuals. Therefore, we have withheld this information under section 40 of the FOIA. Question 8 Based on the independent medical assessor’s description of the assessed conditions they have been able to identify from the claimant's medical records, fewer than five GBS claims made from the Parliamentary Constituency of Angus have been received by the VDPS. Therefore, as detailed above in accordance with section 40 (2) and section 41 of FOIA we are unable to provide figures for successful and unsuccessful claims. The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the independent medical assessor provides a description of the assessed conditions they have been able to identify from the claimant's medical records. This can sometimes be a mixture of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form. All data provided relates to the conditions listed by the independent medical assessor in the assessment report. Therefore, the total number of GBS claims made from the Parliamentary Constituency of Angus awaiting independent medical assessment is unknown.

CVD-COVID-UK, co-ordinated by the British Heart Foundation (BHF) Data Science Centre (https://bhfdatasciencecentre.org/), is one of the NIHR-BHF Cardiovascular Partnership’s National Flagship Projects.

CVD-COVID-UK aims to understand the relationship between COVID-19 and cardiovascular diseases through analyses of de-identified, pseudonymised, linked, nationally collated health datasets across the four nations of the UK. The consortium has over 400 members across more than 50 institutions including data custodians, data scientists and clinicians, all of whom have signed up to an agreed set of principles with an inclusive, open and transparent ethos.

Approved researchers access data within secure trusted/secure research environments (TREs/SDEs) provided by NHS England (England), the National Safe Haven (Scotland), the Secure Anonymised Information Linkage (SAIL) Databank (Wales) and the Honest Broker Service (Northern Ireland). A dashboard of datasets available in each nation’s TRE can be found here: https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/

This dataset represents the linked datasets in SAIL Databank’s TRE for Wales and contains the following datasets: • Welsh Longitudinal GP Dataset - Welsh Primary Care (Daily COVID codes only) (GPCD) • Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care • Critical Care Dataset (CCDS) • Emergency Department Dataset Daily (EDDD) • Emergency Department Dataset (EDDS) • Outpatient Database for Wales (OPDW) • Outpatient Referral (OPRD) • Patient Episode Dataset for Wales (PEDW) • COVID-19 Test Results (PATD) • COVID-19 Test Trace and Protect (CTTP) - Legacy • COVID-19 Shielded People List (CVSP) • SARS-CoV-2 viral sequencing data (COG-UK data)-Lineage/Variant Data-Wales (CVSD) • Covid Vaccination Dataset (CVVD) • Annual District Death Daily (ADDD) • Annual District Death Extract (ADDE) • COVID-19 Consolidated Deaths (CDDS) • Intensive Care National Audit and Research Centre (ICCD) - Legacy - COVID only • Intensive Care National Audit and Research Centre (ICNC) • Welsh Dispensing Dataset (WDDS) - Legacy • Annual District Birth Extract (ADBE) • Maternity Indicators Dataset (MIDS) • National Community Child Health Database (NCCHD) • Care Home Dataset (CARE) • Congenital Anomaly Register and Information Service (CARS) • Referral to Treatment Times (RTTD) • SAIL Dementia e-Cohort (SDEC) • Welsh Ambulance Services NHS Trust (WASD) • Welsh Demographic Service Dataset (WDSD) • Welsh Results Reports Service (WRRS)